Earnings Call
Oct 13, 2026
Q3 FY2026
EPS Estimate
2.52
EPS Actual
2.59
Post-Earnings Close
$248.61
Earnings Reaction
-5.7%
Johnson & Johnson delivered Q3 2026 operational sales growth of 6%, exceeding consensus expectations and accelerating sequentially, with worldwide sales of $25.4 billion positioning the company to exceed $100 billion in annual revenue for the first time in its 140-year history. Adjusted diluted EPS of $2.59 declined 7.5% year-over-year, primarily due to $7 billion in charges related to the Firefly Bio acquisition, Cell BioMedicines collaboration, and the proposed $5.5 billion talc litigation settlement, though the underlying operational performance remained solid. The Innovative Medicine segment drove results with 7.9% operational growth, led by exceptional momentum in oncology (up 17%), where the multiple myeloma portfolio continues to dominate with 80% of patients receiving J&J therapy, and immunology (Tremfya up 68%, ICOTYDE off to a strong launch with 20,000 patients initiated). MedTech underperformed expectations with only 2.5% growth, a material disappointment that management attributed to concentrated headwinds outside the U.S., including volume-based procurement pressures in China, competitive intensity in electrophysiology particularly in Asia-Pacific, and incremental disruption from Middle East geopolitical tensions, alongside Abiomed's continued weakness. Management raised full-year 2026 guidance, now expecting operational sales growth of 6.7%
Report generated on Oct 13, 2026
AI-generated earnings analysis. Not investment advice.
Chief Executive Officer
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
Read the full JNJ analysis
The complete report, with key themes, analyst Q&A summary, notable quotes, and market context — is free with an account. No password, no card.